

Index

abdominal hysterectomy risk of persistent post-operative pain, 46 A-beta fibers, 8, 14–15 response to injury, 25 Abixa™, 319 acetaminophen 211–212 sites of analgesic activity, 59 <i>See also</i> tramadol plus acetaminophen. acetaminophen injectable 258–261 acetaminophen oral and rectal 256–7 acid sensing ion channels (ASICs) ACTIQ™, 131 Acurox™ formulation, 466 acute pain, 5–6, 13 addiction <i>See</i> opioid dependence, 170 A-delta fibers, 3, 8–9, 14 adenosine receptor agonists/ antagonists, Adlea™, 500 Adolonta, 137 adrenergic and serotonergic pain suppression adrenergic and serotonergic receptors, 328 descending pain pathways, 329 norepinephrine, 329 serotonin, 329 Advil™, 215 AeroLEF™, 444 Ahist™, 391 Akatinol, 319 Akten, 279 Alavert™, 391 Algix, 243 Allegra®, 391 Aller-chlor®, 391 Alleve™, 221 allodynia, 5, 14, 16, 24, 30, 76 alpha-2 adrenergic agonists sites of analgesic activity, 62 alvimopan, 420–22 bowel obstruction patients, 422 amantadine, 313, 326–7 American Society of Anesthesiologists Task Force on Acute Pain Management, 211 amethocaine gel. <i>See</i> Ametop Gel™	Ametop Gel™, 283–7 amputation risk of persistent post-operative pain, 46 Amrix, 362 Anacin™, 252 analgesic gaps, 53 analgesic ladder (WHO), 253 analgesic sites of action, 62 analgesic targets. <i>See</i> novel targets for new analgesics analgesics and adjunct agents interference with pain signaling, 1 variety available, 1 Anaprox™, 221 Anesject™, 316 Anestacon, 279 Anorfin™, 157 antibody PG110, 513 anticoagulants and regional anesthesia, 210 anticoagulated patients, 205 antiplatelet agents, 207 complications in peripheral nerve blocks, 209 direct thrombin inhibitors (DTIs), 208 fondaparinux (Arixtra), 207 heparin, 206 herbal therapies, 208 low molecular weight heparin (LMWH), 207 oral anticoagulants (warfarin), 207 potential complications, 206 anticonvulsant analgesics, 294 adverse effects, 293 first generation drugs, 292 mechanisms of action, 292 second generation drugs, 292 anticonvulsants 341–5 sites of analgesic activity, 60 link between pain and depression, 338 monoamine oxidase inhibitors (MAOIs), 338 SNRIs, 341 SSRIs, 338 tricyclic antidepressants (TCAs), 338 antidepressants sites of analgesic activity, 62 antiemetics, oral. <i>See</i> aprepitant antiemetics, parenteral, combined therapy, 400 droperidol, 399–400 metoclopramide, 399–400 ondansetron, 398, 400 opioid-induced nausea and vomiting (OINV), 397 postoperative nausea and vomiting (PONV), 397 anti-epileptic drugs (AED). <i>See</i> anticonvulsant analgesics antihistamines, 391–6 anti-nerve growth factor, 512–3 antibody PG110, 513 aprepitant, 401–4 Arcoxia, 243 Aredia, 413 Arthrotec™, 229, 231 aspirin, 252–255 Astramorph/PF, 197 Ativan, 365 ATP-binding cassette, sub-family B, member 1 (ABCB1), 38 Atretol®, 301 Auxib, 243 Avinza®, 86 Axid®, 391 baclofen, 363, 379–82 Baycadron®, 388 Bayer Aspirin™, 252 Beforal™, 154 behavioral treatments, 33 Benadryl, 361 Benadryl®, 391 Bextra, 213 Bier block, 270 Bier, August, 332 bradykinin, 8 bradykinin receptors, brain-derived neurotrophic factor (BDNF), breast surgery risk of persistent post-operative pain, 46 Brevinaze™, 316 buffered aspirin. <i>See</i> aspirin Bufferin™, 252
--	---

Index

- bupivacaine, 276
 adverse events, 276
 chemical name, 274
 chemical structure, 274
 common doses, 275
 contraindications, 275
 drug class, 274
 drug clearance and elimination, 274
 drug interactions, 275
 generic name, 274
 indications, 274
 major and minor sites of action, 274
 manufacturer, 274
 metabolic pathways, 274
 mode of activity, 274
 multimodal analgesia, 275
 potential advantages, 275
 potential disadvantages, 276
 receptor interactions, 274
 toxicity, 275
 trade/proprietary names, 274
 treatment of adverse events, 276
- Buprenex™, 157
- buprenorphine, 159
 acute pain relief, 158
 chemical formula, 157
 chemical name, 157
 chemical structure, 157
 description, 157
 drug class, 157
 epidural administration, 158
 generic name, 157
 intrathecal administration, 158
 intravenous administration, 159
 manufacturers, 157
 pharmacodynamics, 157
 pharmacokinetics, 157
 potential advantages, 159
 routes of administration, 159
 side effects, 157
 sublingual administration, 159
 trade/proprietary names, 157
- buprenorphine transdermal, 483
 chemical formula, 481
 chemical name, 481
 chemical structure, 481
 common doses/uses, 482
 contraindications, 482
 description, 482
 drug class, 481
 drug interactions, 483
 drug related adverse events, 483
 generic name, 481
 major and minor sites of action, 482
 manufacturers, 481
 potential advantages, 483
 potential disadvantages, 483
- proprietary names, 481
 risk of abuse, 483
 toxicity, 483
 withdrawal, 483
- Buprex™, 157
- Buprine™, 157
- butalbital. *See* Fioricet; Fiorinal
- butorphanol, 156
 adverse events, 156
 chemical formula, 154
 chemical name, 154
 contraindications, 155
 cost, 156
 description, 154
 dose guide, 155
 drug interactions, 156
 general pharmacology, 154
 generic names, 154
 indications, 155
 labor analgesia, 155
 manufacturers, 154
 mechanism of action, 154
 metabolism, 155
 precautions, 156
 relative contraindications, 156
 structure, 154
 trade/proprietary names, 154
 uptake and elimination, 155
 use as preoperative/preanesthetic medication, 155
 use in balanced anesthesia, 155
- BuTrans™, 481
- C fibers, 3, 8–9, 14
- calcitonin gene-related peptide (CGRP), 14
- calcitonin gene-related peptide (CGRP) receptors, 154–155
- calcium (Ca²⁺) channels, 429–431
- Caldolor™, 218
- Cannabidiol. *See* cannabinoid agonists
- cannabinoid agonists, 496
 cannabinoids, 493
 chemical names, 492
 chemical structures, 492
 common doses/uses, 495
 contraindications, 495
 drug class, 492
 drug related adverse events, 496
 generic names, 492
 indications, 494
 manufacturers, 492
 mode of activity, 494
 potential advantages, 495
 potential disadvantages, 496
 trade/proprietary names, 492
See also peripheral cannabinoid receptor agonists, 496
- cannabinoid receptors
- Cannabis sativa*, 492, 497
- capsaicin. *See* injectable capsaicin; topical capsaicin
- carbamazepine, 293
 absorption, 302
 acute toxicity, 304
 adverse reactions, 305
 black box warning, 302
 cautions, 303
 chemical class, 301
 chemical name, 301
 chemical structure, 301
 common doses, 304
 contraindications, 303
 cost guide, 304
 description, 301
 dialysis, 302
 distribution, 302
 drug class, 301
 drug interactions, 304
 excretion, 302
 indications, 302
 metabolism, 302
 mode of activity, 301
 potential advantages, 304
 potential disadvantages, 305
 trade/proprietary names, 301
- Carbatrol, 292, 301
- cardiac effects of poorly controlled pain, 27
- carisoprodol, 361
- carpal tunnel syndrome, 23
- Cataflam™, 229
- Catapres™, 330
- Catapres-TTS™, 330
- catecholamines
 response to poorly controlled pain, 26
- catechol-O-methyl transferase (COMT), 38
- Celebrex, 213, 238
- celecoxib, 213, 242
 absorption, 238
 chemical structure, 238
 circadian effects, 239
 contraindications, 240
 description, 238
 distribution, 238
 drug interactions, 241
 drug related adverse events, 242
 excretion, 239
 generic name, 238
 indications, 240
 manufacturer, 238
 mechanism of action, 238
 metabolism, 239
 overdose, 242
 pharmacokinetics, 239
 potential advantages, 241
 potential disadvantages, 242

- routes of administration, 240
 - trade name, 238
 - Centers for Epidemiologic Studies
 - Depression scale (CES-D), 345
 - central pain, 6
 - central pain syndrome, 23
 - central sensitization, 24
 - Cesamet[®], 492
 - Cesarean section
 - risk of persistent post-operative pain, 46
 - chloride (Cl⁻) channels, 255
 - Chlor-Trimeton[®], 391
 - chlorzoxazone, 360
 - chronic pain, 6, 14
 - chronic post-surgical pain *See* persistent post-operative pain
 - CHRONOGESIC[™], 467
 - Clarinox[®], 391
 - Claritin[®], 391
 - classification of pain
 - approaches to classification, 3
 - neuropathic pain, 4
 - nociceptive pain, 3–4
 - physiological pain, 3–4
 - clinical effects of pain, 3
 - clinical implications of hyperalgesia, 22
 - clonidine (neuraxial)
 - See* neuraxial clonidine
 - hydrochloride, 332
 - clonidine (transdermal and parenteral), 332
 - chemical name, 330
 - chemical structure, 330
 - common doses, 331
 - contraindications, 331
 - description, 330
 - drug clearance and elimination, 331
 - drug related adverse events, 332
 - indications (approved/non-approved), 331
 - major and minor sites of action, 330
 - manufacturer, 330
 - metabolic pathways, 331
 - mode of activity, 331
 - potential advantages, 331
 - potential disadvantages, 332
 - receptor interactions, 331
 - trade/proprietary names, 330
- CNS pain pathophysiology, 24
- cocaine
 - discovery of local anesthetic properties, 267
- codeine, 100
 - chemical name, 98
 - chemical structure, 98
 - common doses, 100
 - contraindications, 99
 - description, 99
 - drug class, 98
 - drug related adverse events, 100
 - generic name, 98
 - indications, 99
 - manufacturer, 98
 - metabolic pathways, 99
 - mode of activity, 99
 - potential advantages, 100
 - potential disadvantages, 100
 - sites of activity, 99
 - trade/proprietary names, 98
- codeine compounds, 99
- cognitive behavior therapy (CBT), 33
- cognitive therapy, 33
- combination analgesics *See* Fioricet; Fiorinal
- Combunox[™], 105
- Contramal, 137
- corticosteroids
 - analgesic effects of IV glucocorticoids, 386
 - articular glucocorticoids, 386
 - clinical actions of glucocorticoids, 384
 - clinical effects of glucocorticoids, 387
 - description, 383
 - glucocorticoids for analgesic injection, 387
 - mechanisms of action, 383
 - molecular mechanisms of glucocorticoids, 383
 - neuraxial glucocorticoids, 386
 - side effects of glucocorticoids, 387
- corticosteroids, oral, 390
 - common doses and uses, 390
 - contraindications, 390
 - drug interactions, 390
 - drug related adverse events, 390
 - indications, 389
 - mode of activity, 389
 - potential advantages, 390
 - potential disadvantages, 390
 - side effects, 390
- COX (cyclooxygenase), 25
- COX (cyclooxygenase) enzymes, 212
- COX-2 (cyclooxygenase-2), 15, 25
- COX-2 inhibitors, 214
 - adverse effects, 211
 - postoperative pain management, 212
 - role in multimodal analgesia, 211
 - role in preemptive analgesia, 212
 - sites of analgesic activity, 59
 - widespread usage, 211
- Cuivasal, 279
- cyclobenzaprine, 362, 372
 - chemical formula, 370
 - chemical name, 370
 - chemical structure, 370
 - common doses/uses, 371
 - contraindications, 371
 - cost, 371
 - description, 370
 - drug class, 370
 - drug clearance and elimination, 370
 - drug related adverse events, 371
 - generic name, 370
 - indications (approved/non-approved), 370
 - manufacturer, 370
 - metabolism, 370
 - overdose, 371
 - potential advantages, 371
 - potential disadvantages, 371–372
 - proprietary name, 370
 - side effects, 372
- cyclooxygenase (COX), 25
- cyclooxygenase (COX) enzymes, 212
- cyclooxygenase-2 (COX-2), 15
- Cymbalta, 353
- cytochrome CYP2D6
 - genetic variations, 39
- cytokine family, 438
- cytokines, 8
- Damason-P[™], 112
- dantrolene, 362
- Decadron[®], 388
- delta-9-tetrahydrocannabinol. *See* cannabinoid agonists
- Deltacortisone[®], 388
- Deltadehydrocortisone[®], 388
- Deltasone[®], 388
- Demerol[™], 94
- Depakene, 292
- Depakon, 292
- Depobupivacaine, 471
- DepoDur[®], 194
- depression and pain. *See* antidepressant analgesics
- descending control of pain, 12
- descending pain pathways, 329
- Desyrel[™], 351
- DETERx technology, 465
- dexamethasone
 - chemical name, 388
 - chemical structure, 388
 - common doses and uses, 390
 - contraindications, 390
 - drug class, 388
 - drug interactions, 390
 - drug related adverse events, 390
 - generic name, 388
 - indications, 389
 - manufacturers, 388
 - mode of activity, 389
 - potential advantages, 390

Index

- potential disadvantages, 390
- proprietary names, 388
- side effects, 390
- dexmedetomidine, 33
 - chemical name, 335
 - chemical structure, 335
 - common doses and uses, 336
 - contraindications, 336
 - drug class, 335
 - drug related adverse events, 337
 - generic name, 335
 - indications, 336
 - manufacturers, 335
 - mode of activity, 335
 - potential advantages, 336
 - potential disadvantages, 337
 - proprietary name, 335
- DexPak®, 388
- dextromethorphan, 313, 324
 - brand names/trade names, 321
 - chemical formula, 321
 - chemical name, 321
 - chemical structure, 321
 - common doses/uses, 323
 - contraindications, 323
 - description, 322
 - drug abuse, 324
 - drug class, 321
 - drug interactions, 324
 - efficacy in acute and chronic pain, 323
 - generic names, 321
 - manufacturers, 321
 - mode of activity, 322
 - potential advantages, 324
 - potential disadvantages, 324
 - treatment of acute poisoning, 324
- diabetic neuropathy, 16, 23
- Diastat, 365
- diazepam, 362
 - chemical structure, 365
 - common doses/uses, 367
 - contraindications, 366
 - drug class, 365
 - drug clearance and elimination, 366
 - drug interactions, 367
 - drug related adverse events, 367
 - generic name, 365
 - indications (approved/non-approved), 366
 - manufacturer, 365
 - metabolic pathways, 366
 - mode of activity, 366
 - potential advantages, 367
 - potential disadvantages, 367
 - proprietary names, 365
 - receptor interactions, 366
 - sites of action, 365
 - toxicity, 367
- treatment of adverse events, 367
- diclofenac gel, 228
 - chemical formula, 225
 - chemical name, 225
 - chemical structure, 225
 - common doses/uses, 227
 - contraindications, 227
 - description, 226
 - drug class, 225
 - drug related adverse events, 228
 - generic name, 225
 - indications, 227
 - manufacturer, 225
 - potential advantages, 228
 - potential disadvantages, 228
 - trade/proprietary name, 225
- diclofenac injectable, 235
 - brand/proprietary name, 232
 - chemical formula, 232
 - chemical structure, 232
 - contraindications, 233
 - description, 232
 - drug class, 232
 - generic name, 232
 - indications, 233
 - manufacturer, 232
 - mode of activity, 233
 - potential advantages, 235
- diclofenac oral, 231
 - chemical formula, 229
 - chemical name, 229
 - chemical structure, 229
 - common doses/uses, 231
 - contraindications, 231
 - description, 229
 - drug class, 229
 - drug clearance and elimination, 230
 - drug interactions, 231
 - drug related adverse events, 231
 - generic name, 229
 - indications, 230
 - major and minor sites of action, 229
 - manufacturers, 229
 - metabolic pathways, 230
 - potential advantages, 231
 - potential disadvantages, 231
 - proprietary names, 229
 - receptor interactions, 229
- diclofenac patch, 228
 - chemical name, 225
 - chemical structure, 225
 - common doses/uses, 227
 - contraindications, 227
 - description, 226
 - drug class, 225
 - drug related adverse events, 228
 - generic name, 225
 - indications, 227
 - manufacturer, 225
- potential advantages, 228
- potential disadvantages, 228
- trade/proprietary name, 225
- diclofenac plus PPI, 231
 - chemical formula, 229
 - chemical name, 229
 - chemical structure, 229
 - common doses/uses, 231
 - contraindications, 231
 - description, 229
 - drug class, 229
 - drug clearance and elimination, 230
 - drug interactions, 231
 - drug related adverse events, 231
 - generic name, 229
 - indications, 230
 - major and minor sites of action, 229
 - manufacturers, 229
 - metabolic pathways, 230
 - potential advantages, 231
 - potential disadvantages, 231
 - proprietary name, 229
 - receptor interactions, 229
- diethylamine salicylate, 410
- dihydrocodeine, 99
- Dilantin, 292
- Dilaudid™, 115, 187
- Dilocol™, 115
- diphenhydramine, 361
- diphenhydramine hydrochloride
 - chemical structure, 391
- Dolophine®, 127
- dorsal rhizotomy, 34
- dorsal root ganglia (DRG), 8
- dronabinol. *See* cannabinoid agonists
- droperidol, 399–400
- Drug Effects Questionnaire (DEQ), 93
- duloxetine, 356
 - absorption, 354
 - chemical formula, 353
 - chemical name, 353
 - chemical structure, 353
 - clinical pearls, 356
 - common doses, 355
 - contraindications, 354
 - description, 354
 - discontinuing duloxetine, 355
 - distribution, 354
 - drug abuse and dependence, 356
 - drug interactions, 355
 - drug related adverse events, 355
 - generic name, 353
 - indications, 354
 - manufacturer, 353
 - metabolism and elimination, 354
 - mode of activity, 354
 - overdosage, 356
 - pharmacokinetics, 354
 - potential advantages, 355

- potential disadvantages, 356
- precautions, 354
- proposed mechanism of action, 354
- receptor interactions, 354
- trade name, 353
- warnings, 354
- Duncaine, 279
- Duraclon™, 332
- Duragesic™, 134
- Duramorph, 181, 197
- Dyloject®, 232
- Dynastat™, 245
- dysesthesia, 16, 30
- Ebov, 242
- EC-Naprosyn™, 221
- Ecotrin™, 252
- Ecoxib, 242
- ectopic foci, 24
- EDACS™ technology, 465
- Elavil™, 347
- Embeda™, 90
- EMBEDA™, 466
- Emend, 401
- EMLA, 279
- EMLA™, 285
 - application area and time by age and weight, 285
 - chemical structure, 283
 - contraindications, 285
 - description, 284
 - generic name, 283
 - how to use, 285
 - manufacturer, 283
 - mode of action, 284
 - pharmacology, 284
 - potential advantages, 285
 - potential disadvantages, 285
 - recommended maximum dose by age and weight, 285
 - trade/proprietary name, 283
- emotional effects of poorly controlled pain, 28
- Empirin™, 252
- Endodan, 101
- endogenous opioids, 57
- endorphins, 57
- enkephalins, 14, 57
- Entereg™, 420
- Epidemiological Studies Depression Scale, 343
- epidural buprenorphine, 158
- epidural catheter evaluation, 204
 - before dosing, 201
 - general considerations, 200
 - how to determine initial dosing, 201
 - patient in pain in Surgical Care Unit or Intensive Care Unit, 204
 - patient in pain in the postoperative care unit (PACU), 202
 - symptom management, 204
- epidural fentanyl, 186
 - chemical name, 184
 - chemical structure, 184
 - common doses/uses, 186
 - contraindications, 185
 - description of fentanyl, 184
 - drug class, 184
 - drug related adverse events, 186
 - generic name, 184
 - indications, 185
 - manufacturer, 184
 - mode of activity, 185
 - potential advantages, 186
 - potential disadvantages, 186
 - trade name, 184
- epidural hydromorphone, 190
 - chemical name, 187
 - chemical structure, 187
 - continuous epidural infusion, 188
 - contraindications, 188
 - description, 187
 - dosing, 189
 - drug class, 187
 - drug clearance and elimination, 188
 - drug related adverse events, 190
 - epidural patient controlled analgesia (PCA), 189
 - generic name, 187
 - indications, 188
 - intermittent bolus dosing, 188
 - major and minor sites of action, 187
 - manufacturer, 187
 - metabolic pathways, 188
 - potential advantages, 190
 - potential disadvantages, 190
 - proprietary names, 187
- epidural morphine, 184
 - adverse events, 184
 - availability, 183
 - chemical structure, 181
 - common doses, 183
 - contraindications, 182
 - drug class, 181
 - drug clearance and elimination, 181
 - drug interactions, 183–184
 - generic name, 181
 - historical development, 181
 - indications, 182
 - manufacturer, 181
 - metabolic pathways, 181
 - mode of activity, 181
 - name of analgesic agent, 181
 - potential advantages, 183
 - potential disadvantages, 184
 - receptor interactions, 181
 - treatment of adverse events, 184
 - See also extended-release epidural morphine, 197
- epidural sufentanil
 - chemical name, 191
 - chemical structure, 191
 - chronic pain patients, 192
 - common doses/uses, 192
 - contraindications, 192
 - cost, 193
 - description, 191
 - drug class, 191
 - drug interactions, 193
 - drug related adverse events, 193
 - generic name, 191
 - indications, 192
 - labor and delivery, 191
 - manufacturer, 191
 - mode of activity, 191
 - post operative pain management, 192
 - potential advantages, 192
 - potential disadvantages, 193
 - trade name, 191
- Equetro®, 301
- Ereska®, 440
- etoricoxib, 213
 - chemical name, 243
 - chemical structure, 243
 - common doses, 244
 - contraindications, 244
 - description, 243
 - drug class, 243
 - drug clearance and elimination, 243
 - drug related adverse events, 244
 - generic names, 243
 - indications (non-approved in the US), 243
 - manufacturer, 243
 - metabolic pathways, 243
 - mode of activity, 243
 - potential advantages, 244
 - potential disadvantages, 244
 - proprietary names, 243
 - sites of action, 243
- Etoxicib, 243
- Etozox, 243
- Eutectic Mixture of Local Anesthetics
 - See EMLA™
- Exalgo™, 448
- Exparel™, 471
- extended duration bupivacaine, 475
 - chemical formula, 471
 - chemical name, 471
 - chemical structure, 471
 - controlled-release delivery systems, 472
 - drug class, 471
 - generic names, 471
 - liposomal bupivacaine, 474
 - liposomal carriers, 472

Index

- manufacturer, 471
 microsphere delivery, 473
 trade/proprietary names, 471
 extended-release epidural
 morphine, 197
 approved doses, 195
 availability, 196
 chemical name, 194
 chemical structure, 194
 clinically useful dosing, 195
 contraindications, 195
 cost, 196
 description, 194
 dosing, 195
 drug class, 194
 drug clearance and elimination, 194
 drug interactions, 196
 drug related adverse events, 197
 generic name, 194
 how supplied, 195
 indications, 194
 major and minor sites of action, 194
 manufacturer, 194
 metabolic pathways, 194
 mode of activity, 194
 potential advantages, 196
 potential disadvantages, 197
 receptor interactions, 194
 toxicity, 196
 trade/proprietary name, 194
 treatment of adverse events, 197
 warnings, 196
 extended-release morphine sulfate.
 See morphine sulfate controlled-release
 Exxiv, 251

 Felbatol, 292
 fentanyl
 See epidural fentanyl; inhaled fentanyl; iontophoretic transdermal fentanyl, 186
 fentanyl oral and buccal, 134
 chemical structure, 131
 common doses, 133
 contraindications, 132
 description, 131
 drug class, 131
 drug interactions, 133
 drug related adverse events, 134
 generic names, 131
 indications (approved/non-approved), 132
 manufacturer, 131
 mode of activity, 132
 potential advantages, 133
 potential disadvantages, 134
 toxicity, 134
 trade/proprietary names, 131
 Fentanyl TAIFUN®, 444

 fentanyl transdermal system, 136
 chemical name, 134
 chemical structure, 134
 common doses, 135
 contraindications, 135
 description, 134
 drug class, 134
 drug related adverse events, 136
 generic name, 134
 indications (approved/non-approved), 135
 manufacturer, 134
 mode of activity, 135
 potential advantages, 135
 potential disadvantages, 136
 trade/proprietary name, 134
 treatment of adverse events, 136
 FENTORA™, 131
 fexofenadine hydrochloride
 chemical structure, 391
 Fioricet, 265
 advantages of combination analgesics, 265
 adverse effects, 265
 clinical studies, 264
 combination analgesics, 263
 contraindications, 264
 description, 263
 drug class, 262
 drug structures, 262
 generic name, 262
 indications, 263
 manufacturer, 262
 pharmacokinetics and pharmacodynamics, 264
 precautions, 265
 side effects, 265
 trade name, 262
 treatments for chronic headaches, 263
 Fiorinal, 265
 advantages of combination analgesics, 265
 adverse effects, 265
 clinical studies, 264
 combination analgesics, 263
 contraindications, 264
 description, 263
 drug class, 262
 drug structures, 262
 generic name, 262
 indications, 263
 manufacturer, 262
 pharmacokinetics and pharmacodynamics, 264
 precautions, 265
 side effects, 265
 trade name, 262
 treatments for chronic headaches, 263
 Fiorinol™, 253
 Flector® Patch, 225

 Flexeril®, 362, 370, 372
 flexible approach to pain management, 71
 Fosaprepitant, 401, 403
 chemical name, 401
 chemical structure, 401
 four step approach to pain management
 common sense guidelines, 69
 rationale for, 67

 G protein-coupled receptors, 24
 GABA (γ -aminobutyric acid), 14
 gabapentin, 292, 293, 297
 chemical structure, 294
 common doses, 297
 contraindications, 296
 description, 295
 drug class, 294
 drug interactions, 295
 drug related adverse events, 297
 generic name, 294
 indications, 296
 manufacturer, 294
 mode of activity, 295
 overdose and treatment, 297
 pharmacodynamics, 295
 pharmacokinetics, 295
 potential advantages, 297
 potential disadvantages, 297
 precaution and instruction for patients, 297
 trade name, 294
 gabapentinoids, 292–293
 Gabitril, 292
 genetic factors
 risk of persistent post-operative pain, 48
 genetic factors in pain response, 40
 ATP-binding cassette, sub-family B, member 1 (ABCB1), 38
 catechol-O-methyl transferase (COMT), 38
 cytochrome CYP2D6, 39
 guanosine triphosphate cyclohydrolase-1 (GCH1), 40
 IL-1 (interleukin-1), 39
 melanocortin-1-receptor (MC1R), 39
 mu opioid receptor (MOR), 37
 pain phenotype, 40
 UGT, 40
 genetics
 novel analgesic targets, 254
 Genpril, 215
 glutamate receptor agonists/antagonists, 459–460
 Gravocain, 279
 guaifenesin, 360
 guanosine triphosphate
 cyclohydrolase-1 (GCH1), 40

- Habitrol, 484
Helicobacter pylori, 213
heterosensitization, 16
histamine, 8
hydrocodone, 99
 See also opioid plus ibuprofen compounds.
hydrocodone bitartrate, 112–114
 chemical formula, 112
 chemical name, 112
 chemical structure, 112
 common doses, 114
 contraindications, 113–114
 description, 112
 drug class, 112
 drug related adverse events, 114
 generic names, 112
 indications (approved and non-approved), 113
 major and minor sites of action, 112
 manufacturers, 112
 metabolic pathways, 113
 mode of activity, 113
 potential advantages, 114
 potential disadvantages, 112
 proprietary names, 112
 receptor interactions, 112
hydromorphone extended release, 455
 chemical formula, 448
 chemical name, 448
 chemical structure, 448
 common doses/uses, 451
 contraindications, 451
 description, 449
 diversion and abuse, 451
 drug class, 448
 drug interactions, 451
 drug related adverse events, 451–452
 generic name, 448
 indications, 451
 manufacturers, 448
 mode of activity, 449
 potential advantages, 451
 potential disadvantages, 451–452
 toxicity, 451
 trade name, 448
hydromorphone (oral and parenteral), 118
 chemical formula, 115
 chemical name, 115
 chemical structure, 115
 common doses, 117
 contraindications, 116
 description, 115
 drug class, 115
 drug related adverse events, 118
 generic names, 115
 indications, 116
 manufacturers, 115
 mode of activity, 116
 potential advantages, 117
 potential disadvantages, 118
 trade/proprietary names, 115
hydromorphone epidural
 See epidural hydromorphone.
hydromorphone extended release, 448–451
 adverse effects, 451
 chemical formula, 448
 chemical name, 448
 chemical structure, 448
 contraindications, 451
 description, 448–449
 drug class, 448
 formulations, 449–451
 generic name, 448
 indications, 450–451
 manufacturers, 448
 mode of action, 447
 proprietary/trade names, 448
hydromorphone OROS™ technology, 467, 469
HydroStat™, 115
hyperalgesia, 30
 allodynia, 24
 clinical implications, 22
 IASP definition, 17
 loss of spinal inhibitory mechanisms, 24
 opioid induced, 77
 primary hyperalgesia, 18
 production of new nerve fibers, 24
 secondary hyperalgesia, 21
hyperalgesia, 5, 14, 24
hyperesthesia, 76
hypoalgesia, 30
hypoesthesia, 30
hysterectomy
 risk of persistent post-operative pain, 46
Ibu, 215
Ibudone™, 105
ibuprofen, 215–217
 chemical name, 215
 chemical structure, 215
 common doses, 216
 contraindications, 216
 description, 215
 drug interactions, 216
 drug related adverse events, 217
 indications (approved/non-approved), 216
 major sites of action, 215
 metabolic pathways, 215
 mode of activity, 215
 oral suspension, 215
 potential advantages, 216
 potential disadvantages, 217
 receptor interactions, 215
 topical creams and gels, 216
 toxicity, 216
 trade/proprietary names, 215
 See also opioid plus ibuprofen compounds.
ibuprofen injectable
 chemical name, 218
 chemical structure, 218
 common doses, 219
 contraindications, 219
 description, 218
 drug class, 218
 drug related adverse reactions, 221
 generic name, 218
 indications, 218
 manufacturer, 218
 mode of activity, 218
 potential advantages, 220
 potential disadvantages, 221
 precautions, 219
 trade name, 218
IL-1 (interleukin-1), 15, 39
IL-1β, 435
IL-6, 435
indomethacin, 229
inflammatory pain, 15
inflammatory response, 24–25
Infumorph, 181, 197
inguinal hernia repair
 risk of persistent post-operative pain, 45
inhaled fentanyl, 448
 chemical formula, 444
 chemical name, 444
 chemical structure, 444
 description, 444
 drug class, 444
 generic name, 444
 manufacturers, 444
 pharmacokinetics, 445
 potential advantages, 448
 potential disadvantages, 448
 proprietary names, 444
 side effects, 448
inhibitory pain modulation, 11
injectable capsaicin, 503
 chemical formula, 500
 chemical name, 500
 chemical structure, 500
 clinical trials and doses, 502
 common doses, 503
 contraindications, 502
 description, 501
 drug class, 500
 generic name, 500
 manufacturer, 500
 mode of activity, 501

Index

- pharmacokinetics/
 pharmacodynamics, 502
- potential advantages and
 disadvantages, 503
- potential indications, 501
- trade name, 500
- Intensol®, 101
- interleukins, 8
- International Association for the Study
 of Pain (IASP)
 - definition of hyperalgesia, 17
 - definition of neuropathic pain, 30
 - definition of pain, 1, 3
- intracranial lesioning, 34
- intranasal ketamine. *See* ketamine
- intranasal
 - chemical formula, 437
 - chemical name, 437
 - chemical structure, 437
 - contraindications, 438
 - description, 437
 - doses, 438
 - drug class, 437
 - drug related adverse events, 439
 - generic name, 437
 - indications, 438
 - manufacturer, 437
 - mode of activity, 438
 - potential advantages, 439
 - potential disadvantages, 439
 - trade name, 437
- intrathecal buprenorphine, 158
- intranasal morphine, 439
- intrathecal morphine, 199
 - analgesic agent, 197
 - brand names, 197
 - chemical formula, 197
 - chemical structure, 197
 - common doses, 199
 - contraindications, 198
 - description, 197
 - drug related adverse events, 199
 - indications, 198
 - mode of activity, 198
 - potential advantages, 199
 - potential disadvantages, 199
- IONSYS™, 455
- iontophoretic transdermal fentanyl,
 457
 - chemical name, 455
 - chemical structure, 455
 - contraindications, 456
 - description, 455
 - dosing, 456
 - drug class, 455
 - generic name, 455
 - indications, 456
 - manufacturer, 455
 - mode of action, 456
 - potential advantages, 457
 - potential disadvantages, 457
 - trade/proprietary name, 455
- Isicaine, 279
- Ivemend, 401
- JNJ-42160443, 512
- Jurnista™, 467
- Kadian, 86
- Keiran™, 316
- Keppra, 292
- Ketaject™, 316
- Ketalar™, 316
- Ketalin™, 316
- Ketamax™, 316
- ketamine, 312, 319
 - chemical formula, 316
 - chemical name, 316
 - chemical structure, 316
 - common doses, 318
 - contraindications, 318
 - description, 316
 - drug class, 316
 - drug related adverse
 events, 319
 - generic name, 316
 - indications, 318
 - manufacturer, 316
 - mode of activity, 317
 - potential advantages, 318
 - potential disadvantages,
 319
 - S (+) ketamine, 312
 - trade names, 316
- ketamine intranasal, 443
 - brand name, 440
 - chemical formula, 440
 - chemical structure, 440
 - contraindications, 441
 - description, 440
 - drug class, 440
 - efficacy and safety, 443
 - generic name, 440
 - indications, 441
 - manufacturer, 440
 - mode of activity, 441
- Keta™, 316
- ketorolac, 237
 - chemical structure, 235
 - common doses, 237
 - contraindications, 236
 - description, 236
 - drug interactions, 237
 - drug related adverse
 events, 237
 - generic name, 235
 - indications, 236
 - manufacturer, 235
 - metabolic activity, 236
 - mode of activity, 236
 - potential advantages, 237
 - potential disadvantages, 237
 - trade name, 235
- kinase modulators,
 kretos, 243
- Lamictal, 292, 306
- Lamictin, 306
- Lamogine, 306
- lamotrigine, 292–293
 - adverse events, 308
 - brand/proprietary names, 306
 - chemical formula, 306
 - chemical name, 306
 - chemical structure, 306
 - common doses/uses, 308
 - contraindications, 307
 - cost, 308
 - description, 306
 - drug class, 306
 - drug clearance and elimination, 307
 - generic name, 306
 - metabolism, 307
 - mode of activity, 307
 - potential advantages, 308
- Leostesin, 279
- Liberaxim™, 115
- lidocaine, 267, 270
 - See also* topical local anesthetics, 283
- lidocaine for neural blockade, 282
 - adverse events, 282
 - chemical names, 279
 - chemical structure/properties, 280
 - common doses/uses, 282
 - contraindications, 282
 - differential blockade, 282
 - duration of action, 281
 - historical development, 280
 - indications, 282
 - interaction with hormone
 replacement therapy, 280
 - manufacturers, 280
 - metabolism, 280
 - mode of activity, 280
 - onset of action, 281
 - pharmacodynamics, 280
 - pharmacokinetics, 280
 - potential advantages, 282
 - potential disadvantages, 282
 - proprietary names, 279
- lidocaine transdermal patch, 291
 - caution, 290
 - chemical structure, 288
 - contraindications, 290
 - description, 288
 - disposal of used patches, 291
 - dosing, 290
 - drug related adverse events, 290

- generic name, 288
- how to use in pain management, 289
- manufacturer, 288
- mode of action, 288
- overdose causes and treatment, 290
- pharmacology, 288
- potential advantages, 289
- potential disadvantages, 289
- trade name, 288
- use during MRI, 290
- Lidoderm, 279
- Lidoderm Patch 5%, 288
- Lidothesin, 279
- Lioresal, 379
- liposomal bupivacaine, 475
- LMX-4TM (liposomal lidocaine), 285
 - chemical structure, 285
 - contraindications**, 285
 - description, 285
 - generic name, 283
 - how to use, 285
 - manufacturer, 283
 - mode of action, 285
 - pharmacology, 285
 - potential advantages, 285
 - potential disadvantages, 285
 - trade/proprietary name, 283
- local anesthetic bone paste, 489
 - chemical formula, 488
 - chemical structure, 488
 - common doses, 489
 - description, 488
 - drug class, 488
 - generic names, 488
 - indications, 488
 - manufacturers, 488
 - mode of activity, 488
 - potential advantages, 489
 - potential disadvantages, 489
 - trade/proprietary names, 488
- local anesthetics, 273
 - additive analgesic effects, 271
 - advantages, 272
 - adverse events, 273
 - amides, 267, 270
 - chemical structure, 267
 - contraindications, 271
 - disadvantages, 272
 - dosages, 271
 - esters, 267, 270–271
 - history of discovery, 267
 - indications, 270
 - local anesthetic plus opioid, 271
 - metabolism, 270
 - mode of action, 268
 - neuro-anatomical correlates of noxious blockade, 270
 - physiochemical correlates of LA activity, 269
 - sites of analgesic activity, 59
 - topical local anesthetics, 287
 - uses for differential block, 268
- lorazepam
 - chemical structure, 365
 - common doses/uses, 367
 - contraindications, 366
 - drug class, 365
 - drug clearance and elimination, 366
 - drug interactions, 367
 - drug related adverse events, 367
 - generic name, 365
 - indications (approved/non-approved), 366
 - metabolic pathways, 366
 - mode of activity, 366
 - potential advantages, 367
 - potential disadvantages, 367
 - proprietary names, 365
 - receptor interactions, 366
 - sites of action, 365
 - toxicity, 367
 - treatment of adverse events, 367
- LortabTM, 118
- lumiracoxib, 213
- Lyrica, 292, 298
- magnesium
 - chemical formula, 325
 - chemical name, 325
 - chemical structure, 325
 - contraindications, 325
 - doses, 326
 - drug related adverse events, 326
 - generic names, 325
 - indications, 325
 - manufacturer, 325
 - mode of activity, 325
 - NMDA receptor antagonist, 314, 326
 - potential advantages, 326
 - potential disadvantages, 326
 - trade names, 325
- Marcain, 274
- Marcaine, 274
- Marinol[®], 492
- Maxidex[®], 388
- McGill Pain Questionnaire, 6
- mechanical hyperalgesia, 14
- medetomidine, 335
- medical factors
 - risk of persistent post-operative pain, 48
- mefanamic acid, 229
- melanocortin-1-receptor (MC1R), 39
- meloxicam
 - chemical formula, 249
 - chemical name, 249
 - chemical structure, 249
 - common doses, 250
 - contraindications, 250
 - description, 249
 - drug class, 249
 - drug interactions, 251
 - drug related adverse events, 251
 - generic name, 249
 - indications, 250
 - manufacturer, 249
 - metabolism, 250
 - mode of action, 249
 - potential advantages, 250
 - potential disadvantages, 251
 - potential indication under investigation, 250
 - trade/proprietary name, 249
- memantine, 314, 321
 - chemical formula, 319
 - chemical name, 319
 - chemical structure, 319
 - clinical use in neuropathic pain, 320
 - common doses, 320
 - contraindications, 320
 - description, 320
 - drug class, 319
 - drug clearance and elimination, 320
 - drug related adverse events, 321
 - generic name, 319
 - indications, 320
 - major and minor sites of action, 320
 - manufacturers, 319
 - metabolic pathways, 320
 - mode of activity, 320
 - potential advantages, 321
 - proprietary names, 319
- meperidine, 98
 - alpha 2 adrenergic receptor effects, 95
 - anticholinergic effect, 94
 - chemical name, 94
 - chemical structure, 94
 - class of drug, 94
 - common doses, 97
 - contraindications, 97
 - description, 94
 - drug clearance and elimination, 95
 - drug related adverse events, 98
 - generic names, 94
 - indications, 96
 - manufacturers, 94
 - metabolic pathways, 95
 - modes of administration, 97
 - neuraxial administration, 97
 - opioid receptor binding, 95
 - oral administration, 97
 - parenteral administration, 97
 - potential disadvantages, 97
 - sites of action, 95
 - sodium channel blocker, 94
 - trade name, 94
- meprobamate, 361

Index

- metaxalone, 361, 374
 chemical formula, 372
 chemical name, 372
 chemical structure, 372
 clinical pearls, 374
 common doses, 373
 contraindications, 373
 cost guide, 373
 drug clearance and elimination, 373
 drug interactions, 374
 drug related adverse events, 374
 how supplied, 373
 indications, 373
 manufacturer, 372
 metabolic pathways, 373
 mode of activity, 373
 overdose, 374
 potential advantages, 374
 potential disadvantages, 374
 trade/proprietary name, 372
 warnings, 373
- methadone, 131
 acute pain crisis in emergency
 room, 129
 adverse events, 131
 chemical formula, 127
 chemical name, 127
 chemical structure, 127
 common doses/uses, 130
 contraindications, 129
 description, 127
 drug class, 127
 drug interactions, 130
 generic name, 127
 indications (approved/
 non-approved), 129
 intraoperative use for prolonged
 postoperative analgesia, 129
 intrathecal and epidural neuraxial
 analgesia, 130
 maintenance for heroin addiction,
 128
 manufacturers, 127
 medical pain, 128
 mode of activity, 128
 NMDA receptor antagonist, 314
 opioid conversion, 130
 postoperative acute surgical pain,
 129
 potential advantages, 130
 potential disadvantages, 131
 trade/proprietary name, 127
- methocarbamol, 360, 369
 chemical name, 368
 chemical structure, 368
 common doses, 369
 contraindications, 368
 cost, 369
 description, 368
 drug class, 368
 drug clearance and
 elimination, 368
 drug related adverse events, 369
 generic name, 368
 indications (approved/
 non-approved), 368
 manufacturer, 368
 metabolism, 368
 mode of activity, 368
 potential advantages, 369
 potential disadvantages, 369
 proprietary name, 368
- methyl salicylate, 409
- methylnaltrexone, 420
 chemical name, 418
 chemical structure, 418
 common dosage, 419
 contraindications, 419
 description, 418
 drug class, 418
 drug related adverse events, 420
 generic name, 418
 indications (approved/
 non-approved), 418
 major and minor sites of
 action, 418
 manufacturer, 418
 metabolic pathways, 418
 mode of activity, 418
 potential advantages, 419
 potential disadvantages, 420
 receptor interactions, 418
 trade/proprietary name, 418
- metoclopramide, 399–400
- micrisimal prostaglandin E synthase-1
 (mPGES-1), 421–422
- Midol, 215
- migraine headaches, 16
- milnacipran, 358
 adverse effects, 358
 chemical formula, 357
 chemical structure, 357
 contraindications, 358
 description, 357
 dosage, 359
 drug class, 357
 drug interactions, 358
 generic name, 357
 indications, 359
 manufacturer, 357
 pharmacokinetics, 357
 pharmacology, 357
 trade/proprietary name, 357
- misoprostol, 229
 contraindications, 230
 drug clearance and elimination,
 230
 mechanism of action, 229
 metabolic pathway, 230
 potential disadvantages, 231
 receptor interactions, 229
See also Arthrotec™, 231
- mixed category pain, 16
- Mobic™, 249
- monoamine oxidase inhibitors
 (MAOIs), 338
- Moradol™, 154
- morphine
 history of, 73
- morphine (oral and parenteral), 82–85
 chemical name, 82
 chemical structure, 82
 class, 82
 common doses, 83
 common side effects, 85
 contraindications, 83
 drug clearance and elimination, 83
 drug interaction, 85
 drug related adverse effects, 85
 fertility, 84
 generic names, 82
 indications, 83
 lactation, 84
 major and minor sites of action, 82
 manufacturers, 82
 metabolic pathways, 83
 multimodal analgesia, 85
 potential advantages, 84
 potential disadvantages, 84
 pregnancy, 84
 receptor interactions, 83
 trade/proprietary names, 82
 treatment of adverse effects, 85
- morphine intranasal. *See* intranasal
 morphine
- morphine neuraxial
See epidural morphine;
 extended-release epidural
 morphine; intrathecal morphine
- morphine sulfate controlled-release, 86
 absorption, 86
 chemical structure, 86
 common doses, 88
 contraindications, 87
 drug class, 86
 drug related adverse events, 89
 excretion, 87
 formulations, 86
 generic names, 86
 indications (approved/
 non-approved), 87
 manufacturers, 86
 metabolic pathway, 87
 metabolism, 87
 mode of activity, 86
 potential advantages, 89
 potential disadvantages, 89
 sites of activity, 86
 trade/proprietary names, 86
 treatment of adverse events, 89

- morphine-6-glucuronide, 478
 - chemical structure, 475
 - description, 475
 - disadvantages, 477
 - drug class, 475
 - generic name, 475
 - manufacturer/developers, 475
 - metabolism, 476
 - pharmacodynamics, 476
 - pharmacokinetics, 476
 - potential advantages and uses, 477
 - randomized controlled trials, 478
- motor cortex stimulation, 35
- Motrin™, 215
- MRI
 - use of lidocaine transdermal patch, 290
- MS Contin®, 86
- multidisciplinary approach
 - neuropathic pain management, 34
- multidisciplinary pain centers, 34
- multimodal analgesia, 275
 - acetaminophen (paracetamol), 59
 - alpha-2 adrenergic agonists, 62
 - anticonvulsants, 60
 - antidepressants, 62
 - COX-2 inhibitors, 59
 - local anesthetics, 59
 - morphine, 85
 - NMDA receptor antagonists, 61
 - NSAIDs, 58
 - opioids, 58
 - SNRIs, 62
 - TCAs (tricyclic antidepressants), 61
- multi-segmental flexion reflexes, 5
- muscle relaxants in pain management
 - baclofen, 363, 364
 - carisoprodol, 361
 - chlorzoxazone, 360
 - cyclobenzaprine, 362
 - dantrolene, 362
 - diazepam (Valium), 362
 - guaifenesin, 360
 - meprobamate, 361
 - metaxalone, 361
 - methocarbamol, 360
 - orphenadrine, 361
 - prescribing considerations, 364
 - tizanidine, 363
- muscle spasm, 5
- myelopathic pain, 6
- myofascial pain, 16
- Nabilone. *See* cannabinoid agonists
- N-acetyl-para-aminophenol (APAP).
 - See* acetaminophen
- Nalbufina™, 150
- nalbuphine
 - abuse liability, 153
 - adverse reactions, 153
 - brand names, 150
 - chemical formula, 150
 - chemical name, 150
 - chemical structure, 150
 - contraindications, 153
 - description, 151
 - dosage, 152
 - drug class, 150
 - drug interactions, 152
 - formulation, 153
 - generic name, 150
 - indications, 151
 - manufacturers, 150
 - pharmacokinetics, 151
 - routes of administration, 153
- Naprelan™, 221
- Naprosyn™, 221
- naproxen, 225
 - absorption, 222
 - adverse events, 224
 - chemical formula, 221
 - chemical name, 221
 - chemical structure, 221
 - common doses/uses, 224
 - contraindications, 224
 - description, 222
 - distribution, 222
 - drug class, 221
 - generic name, 221
 - indications, 223
 - manufacturers, 221
 - mechanism of action, 222
 - metabolism, 222
 - pharmacokinetics and pharmacodynamics, 222
 - potential advantages, 224
 - potential disadvantages, 225
 - toxicity, 225
 - trade/proprietary names, 221
- Naropin, 276
- Nasal Stadol™, 154
- Nemenda™, 319
- neo-spinothalamic tract (nSTT), 11
- neostigmine, 480
 - chemical formula, 479
 - chemical name, 479
 - chemical structure, 479
 - common doses, 480
 - contraindications, 480
 - description, 479
 - drug class, 479
 - drug clearance and elimination, 479
 - generic name, 479
 - how supplied, 479
 - indications for analgesia, 480
 - major and minor sites of action, 479
 - manufacturer, 479
 - metabolic pathways, 479
 - potential advantages, 480
 - potential disadvantages, 480
 - receptor interaction, 479
 - trade name, 479
- neramexane, 314, 508
 - chemical name, 507
 - chemical structure, 507
 - common doses/uses, 508
 - contraindications, 508
 - description, 507
 - drug class, 507
 - drug related adverse effects, 508
 - generic name, 507
 - indications, 507
 - manufacturer, 507
 - mode of activity, 507
 - potential advantages/disadvantages, 508
 - preliminary analgesic trials, 507
- nerve growth factor (NGF), 14
- nerve pain. *See* neuropathic pain
- neuraxial clonidine hydrochloride
 - black box warning, 333
 - chemical name, 332
 - chemical structure, 332
 - common doses, 333
 - contraindications, 333
 - description, 332
 - drug class, 332
 - drug clearance and elimination, 333
 - drug related adverse events, 334
 - indications, 333
 - major and minor sites of action, 332
 - manufacturer, 332
 - metabolic pathways, 333
 - mode of activity, 333
 - potential advantages, 334
 - potential disadvantages, 334
 - receptor interactions, 333
 - trade/proprietary name, 332
- neuraxial glucocorticoids, 386
- neuroablative procedures, 34
- neuroendocrine system
 - responses to poorly controlled pain, 27
- neurogenic inflammation, 25
- neurolytic nerve block, 34
- neuronal plasticity, 16, 45
- Neurontin, 292, 294
- neuropathic pain, 3–4, 15–16
 - assessment, 30
 - causes, 30
 - diagnosis, 30
 - IASP definition, 30
 - perception abnormalities, 30
 - pharmacological management, 17
 - scales and questionnaires, 30
 - screening tools, 30
 - sensory abnormalities, 30
 - sensory examination, 30
 - types of, 30

Index

- neuropathic pain management
 behavioral treatments, 33
 cognitive behavior therapy (CBT), 33
 cognitive therapy, 33
 interdisciplinary team approach, 34
 interventional management, 35
 multidisciplinary treatment, 34
 nerve blocks, 34
 neuroablative procedures, 34
 neurostimulation, 35
 non-pharmacological approaches, 34
 pharmacological management, 31
 psychological interventions, 32
 rehabilitation, 32
- neurotransmitters and receptors, 10
- neurotrophin receptors, 437
- Nicoderm, 484
- Nicorette, 484
- nicotine transdermal, 484–487
 absorption, 485
 adverse reactions, 486
 cautions, 486
 chemical formula, 484
 chemical name, 484
 chemical structure, 484
 common doses, 487
 contraindications, 486
 description, 484
 distribution, 485
 drug abuse and dependence, 486
 drug class, 484
 drug interactions, 487
 generic name, 484
 indications (non-FDA-approved), 486
 manufacturers, 484
 mechanism of action, 485
 metabolism, 485
 pharmacokinetics, 485
 potential advantages, 487
 potential disadvantages, 487
 pregnancy, 486
 trade/proprietary names, 484
- nicotinic receptor agonists/antagonists, 436
- nitric oxide synthase (NOS), 433
- NMDA receptor antagonists, 314
 amantadine, 313, 327
 dextromethorphan, 313, 324
 ketamine, 312, 319
 magnesium, 314, 326
 memantine, 314, 321
 methadone, 314
 neramexane, 314
 sites of analgesic activity, 61
- NMDA receptors
 clinical pharmacology, 314
 description, 310
 function, 312
 structure, 310
- nociceptin, 511
 adverse effects, 511
 description, 508
 history, 509
 Nociceptin-Orphanin FQ agonists for substance abuse, 511
 Nociceptin-Orphanin FQ as an anxiolytic, 511
 Nociceptin-Orphanin FQ CNS distribution, 510
 Nociceptin-Orphanin FQ in inflammatory pain models, 510
 Nociceptin-Orphanin FQ neuropeptide, 509
- nociception, 3, 11
 activation of sensory end organs and/or nerve endings, 8
 and subjective experience of pain, 14
 ascending tracts, 11
 conduction of pain to the spinal cord and medulla, 11
 descending neural pathways, 12
 objective measurement, 14
 stages in pain transmission, 7
 transmission of impulses from spinal cord to supra-spinal structures, 11
- nociceptive nerve fibers, 8
- nociceptive pain, 3–4, 15
- nociceptors, 3
 pain detection and signaling, 1
- nonsteroidal anti-inflammatory drugs. *See* NSAIDs
- Norco™, 112
- norepinephrine, 329
- Norpramin™, 347
- Norspan™, 481
- novel sustained release analgesics
 hydromorphone OROS™ technology, 467, 469
 subcutaneous extended release sufentanil, 467, 470
 transdermal extended release sufentanil, 467, 471
- novel targets for new analgesics, 423–436
 acid sensing ion channels (ASICs), 423
 adenosine receptor agonists/antagonists, 430
 bradykinin receptors, 430
 calcitonin gene-related peptide (CGRP) receptors, 430–431
 calcium (Ca²⁺) channels, 425–427
 cannabinoid receptors, 433
 chloride (Cl⁻) channels, 427
 cytokine family, 434
 economic potential, 423
 enzyme families, 427–429
 glutamate receptor agonists/antagonists, 430–431
 IL-1β, 434
 IL-6, 434
 ion channel families, 423–427
 kinase modulators, 428
 microsomal prostaglandin E synthase-1 (mPGES-1), 423–424
 neurotrophin receptors, 433
 new approaches, 423
 nicotinic receptor agonists/antagonists, 531
 nitric oxide synthase (NOS), 429
 potassium (K⁺) channels, 427
 purinoceptors, 429–430
 receptor families, 429–433
 sodium (Na⁺) channels, 425
 the promise of genetics, 434–435
 TNFα, 434
 transient receptor potential (TRP) channels, 423–425
- NSAIDs, 212–213
 adverse effects, 211
 mechanism of action, 212
 postoperative pain management, 212
 role in multimodal analgesia, 211
 role in preemptive analgesia, 212
See also COX-2 inhibitors, 212
 sites of analgesic action, 58
 widespread usage, 211
- Nubain™, 150
- nuclear receptors, 24
- nucleus raphe magnus, 57
- Nucxia, 243
- Nucynta™, 143
- Numorphan injectable™, 119
- Nuprin, 215
- Nurofen Plus®, 98
- Ofirmev™, 258
- ondansetron, 398, 400
- OPANA ER™, 123
- Opana injectable™, 119
- Opidol™, 115
- opioid agonist plus antagonist analgesics
 abuse liability, 93
 abuse of prescription opioids, 91
 chemical structures, 90
 drug class, 90
 future combinations, 93
 generic names, 90
 manufacturers, 90
 morphine plus naltrexone combination, 92–93

Index

- opioid agonist and antagonist
 - combinations, 92
 - trade/proprietary names, 90
- opioid analgesics, 80
 - benefits and liabilities, 73
 - drug related adverse events, 80
 - future directions for acute pain treatment, 80
 - history of, 73
 - hyperalgesia, 77
 - opioid tolerance and dependence, 77
 - oral analgesic dosing, 79
 - parenteral opioid therapy, 78
 - pharmacokinetics, 76
 - regulation of, 73
- opioid classification, 77
- opioid dependence, 76
 - meanings of the term, 170
 - pain management in dependent patients, 170
 - types of patients, 165
 - withdrawal syndrome, 169
- opioid dosing in pediatric patients, 165–169
 - age classification for pediatric patients, 161
 - general principles of pain management, 161–162
 - initial opiate dosage guide (patients over 6 months old), 162–164
 - initial opiate dosage guide (patients under 6 months old), 164–165
 - opioids as anesthetics (patient under 6 months old), 164–165
 - routine postoperative analgesia, 165
- opioid hyperalgesia, 171
- opioid induced hyperalgesia
 - characteristics, 171
 - clinical and management implications, 174
 - pathophysiology, 172
 - recognition of the condition, 171
- opioid plus ibuprofen compounds
 - chemical names, 105
 - chemical structure of individual drugs, 105
 - common doses (oral), 107
 - contraindications, 107
 - description, 105
 - drug class, 105
 - drug clearance and elimination, 106
 - generic names, 105
 - indications (approved/non-approved), 106
 - major and minor sites of action, 105
 - manufacturers, 105
 - metabolic pathways, 106
 - opioid-sparing effects, 107
 - potential advantages and disadvantages, 107
 - proprietary names, 105
 - receptor interactions, 105
 - side effects, 107
- opioid receptors, 74
 - delta receptors (OPR₁), 73–74
 - kappa receptors (OPR₂), 73–74
 - mu receptors (OPR₃), 73–74
 - sigma-1 receptors, 74
 - sigma receptors, 73
- opioid rotation, 179
 - adverse effects of opioid analgesics, 175
 - guidelines, 179
 - patient variabilities in opioid response, 176
 - tolerability of opioid analgesics, 175
- opioid tolerance, 77, 167
 - acquired tolerance, 167
 - addiction, 76
 - development of, 166
 - innate tolerance, 166
 - learned tolerance, 166
 - pain management in opioid tolerant patients, 170
 - pharmacodynamic tolerance, 167
 - pharmacokinetic tolerance, 166
 - physical dependence, 76
 - pseudo-addiction, 165
 - psychological dependence, 76
 - types of, 167
 - types of patients, 165
- opioid-induced abnormal pain, 171
 - sensitivity, 171
- opioid-induced paradoxical pain, 171
- opioids, 171
 - sites of analgesic activity, 59–60
 - tamper resistant. *See* tamper resistant opioids
- ORADUR™ technology, 465
- oral opioid analgesics, 79
- oral salicylate *See* aspirin
- Orasone®, 388
- OROS™ technology, 465
- Orphanin/FQ, 508
- orphenadrine, 361
- OXN™, 90
- Oxy IR®, 101
- oxycodone, 101–104
 - chemical formula, 101
 - chemical name, 101
 - chemical structure, 101
 - common doses/uses, 103
 - contraindications, 102
 - description, 101
 - drug class, 101
 - drug related adverse effects, 104
 - generic name, 101
 - indications, 102
 - manufacturers, 101
 - metabolism and elimination, 101
 - mode of activity, 101
 - patients with hepatic impairment, 102
 - patients with renal impairment, 102
 - potential advantages, 103
 - potential disadvantages, 103
 - proprietary names, 101
 - respiratory depression, 102
 - See also* opioid plus ibuprofen compounds.
- oxycodone compounds
 - generic names, 101
 - manufacturers, 101
 - proprietary names, 101
- oxycodone controlled release
 - chemical formula, 108
 - chemical name, 108
 - chemical structure, 108
 - contraindications, 110
 - cost/street price, 111
 - description, 108
 - dosage, 110
 - drug abuse and addiction, 111
 - drug class, 108
 - drug clearance and elimination, 109
 - drug interactions, 111
 - drug related adverse events, 111
 - formulations, 111
 - generic name, 108
 - how supplied, 111
 - indications, 109
 - manufacturer, 108
 - metabolic pathways, 109
 - mode of activity, 109
 - potential advantages, 110
 - potential disadvantages, 111
 - proprietary name, 108
 - toxicity, 111
- Oxycontin®, 108
- Oxydose®, 101
- Oxyfast®, 101
- oxymorphone extended release, 123–127
 - absorption, 124
 - chemical formula, 123
 - chemical name, 123
 - chemical structure, 123
 - common doses, 126
 - contraindications, 125
 - description, 124
 - drug class, 123
 - drug clearance and elimination, 124
 - drug related adverse events, 127
 - generic name, 123
 - indications, 125
 - manufacturers, 123
 - metabolic pathways, 124
 - metabolism, 125
 - mode of activity, 124

Index

- potential advantages, 126
- potential disadvantages, 126
- proprietary name, 123
- routes of administration, 126
- oxymorphone injectable, 122
- acute pain management, 121
- chemical formula, 119
- chemical name, 119
- chemical structure, 119
- clinical pharmacology, 121
- common doses, 121
- contraindications, 121
- conversion from oral OPANA to OPANA injection, 122
- cost, 122
- description, 119
- drug class, 119
- drug interactions, 122
- drug related adverse events, 122
- generic name, 119
- historical overview, 120
- indications, 121
- IV-PCA (patient-controlled analgesic), 121
- labor analgesia, 122
- manufacturers, 119
- preparations, 122
- proprietary names, 119
- uses, 121
- Oxytrex™, 90
- Ozurdex®, 388
- pain
 - effects on recovery, 3
 - incidence among patients, 3
 - reasons for minimising discomfort, 3
- pain classifications, 4
- temporal classifications, 14
- pain definitions
 - IASP definition, 1, 3
- pain detection
 - nociceptors, 1
- pain experience
 - and nociception, 14
- pain ladder method of controlling pain, 211
- pain management
 - guidelines for a four step approach, 69
 - moving towards a flexible approach, 71
 - rationale for a four step approach, 67
 - traditional three step approach, 66
- pain pathophysiology
 - cardiac effects, 27
 - CNS pathophysiology, 24
 - definition of pathologic pain, 23
 - emotional and quality of life effects, 28
 - humoral and hormonal responses, 27
 - peripheral nervous system, 25
 - pulmonary effects, 27
 - vascular effects, 27
 - venous thrombotic effects, 28
- pain perception
 - qualitative aspects, 6
- pain signaling, 1
- pain temporality and duration, 6
- PainEase. *See* vapocoolant spray (PainEase)
- paleo-spinothalamic tract (pSTT), 11
- Pallidone™, 448
- Pamelor™, 347
- pamidronate
 - chemical structure, 413
 - common doses, 414
 - contraindications, 413
 - description, 413
 - drug class, 413
 - drug interactions, 414
 - drug related adverse events, 414
 - generic name, 413
 - indications (approved/non-approved), 413
 - manufacturer, 413
 - mode of activity, 413
 - potential advantages, 414
 - potential disadvantages, 414
 - trade/proprietary name, 413
- paracetamol. *See* acetaminophen
- parecoxib, 213
 - chemical formula, 245
 - chemical structure, 245
 - drug class, 245
 - generic name, 245
 - manufacturer, 245
 - trade/proprietary name, 245
- parenteral opioid therapy, 78
- paresthesia, 30
- pathologic pain
 - definition, 23
- patient
 - risk of persistent post-operative pain, 47
- Patient Health Questionnaire (PHQ-9), 345
- pediatric patients. *See* opioid dosing in pediatric patients.
- Pepcid®, 391
- Percocet®, 101
- Percodan®, 101
- Percodan™, 253
- Perfalgan, 258
- periaqueductal gray matter, 57
- peripheral cannabinoid receptor
 - agonists
 - adverse events, 500
 - availability, 500
 - chemical structures, 497
 - contraindications, 499
 - description, 499
 - drug class, 497
 - drug interactions, 499
 - generic names, 497
 - indications (approved/non-approved), 499
 - manufacturer, 497
 - metabolic pathways, 499
 - mode of activity, 499
 - potential advantages, 499
 - potential disadvantages, 500
 - proprietary names, 497
 - toxicity, 499
- peripheral kappa agonist, 491
 - chemical name, 490
 - chemical structure, 490
 - contraindications, 490
 - description, 490
 - drug abuse and dependence, 491
 - drug class, 490
 - drug related adverse events, 491
 - generic name, 490
 - indications (non-approved), 490
 - manufacturer/developer, 490
 - mechanism of action, 490
 - pharmacokinetics, 490
 - potential advantages, 491
 - potential disadvantages, 491
 - trade/proprietary name, 490
- peripheral nervous system pain
 - pathophysiology, 25
- peripheral sensitization, 25
- persistent post-operative pain
 - abdominal hysterectomy, 46
 - amputation, 46
 - breast surgery, 46
 - central nervous system involvement, 43
 - Cesarean section, 46
 - consequences, 41
 - definition, 41
 - epidemiology, 41
 - genetic risk factors, 48
 - historical background, 41
 - identifying patients at risk, 48
 - inguinal hernia repair, 45
 - mechanisms, 45
 - neuronal plasticity, 45
 - non-nerve structures involved, 43
 - pain processes, 43
 - patient risk factors, 47
 - peripheral nervous system involvement, 43
 - predicting, 48

Index

- risk factors, 48
 risk with various operative procedures, 46
 significance, 42
 spinal cord involvement, 43
 structures involved, 43
 surgical/medical risk factors, 48
 thoracic surgery, 45
 persistent post-operative pain
 management, 49–51
 future directions for treatment, 50
 multimodal treatment, 50
 new targets for treatments, 50
 post-operative treatment, 50
 pre-emptive/preventive treatment, 49
 prevention, 49
 phantom limb pain, 46
 pharmacological management of
 neuropathic pain, 17, 31
 Phenergan[®], 391
 phenylbutazone, 229
 phenytoin, 292
 physiological pain, 3–4
 plasticity
 neuronal regeneration, 16
 PMS Hydromorphone[™], 115
 Polistirex[™], 321
 poorly controlled pain
 cardiac effects, 27
 catecholamine responses, 26
 emotional effects, 28
 neuroendocrine responses, 27
 pulmonary effects, 27
 quality of life effects, 28
 stress response to injury, 27
 vascular effects, 27
 venous thrombotic effects, 28
 postherpetic neuralgia, 23
 post-operative pain
 See also persistent post-operative pain.
 potassium (K⁺) channels, 435
 Precedex[®], 335
 prednisone
 chemical name, 388
 chemical structure, 388
 common doses and uses, 390
 contraindications, 390
 drug class, 388
 drug interactions, 390
 drug related adverse events, 390
 generic name, 388
 indications, 389
 manufacturers, 388
 mode of activity, 389
 potential advantages, 390
 potential disadvantages, 390
 proprietary names, 388
 side effects, 390
 Prednisone[®], 388
 preemptive analgesia, 212
 pregabalin, 292–293
 chemical formula, 298
 chemical name, 298
 chemical structure, 298
 contraindications, 299
 description, 298
 drug related adverse effects, 300
 generic name, 298
 indications, 300
 manufacturer, 298
 mechanism of action, 298
 overdose, 300
 pharmacokinetics, 299
 potential advantages, 300
 potential disadvantages, 300
 routes of administration, 299
 trade name, 298
 Prialt[™], 415
 prilocaine, 270, *See* EMLA[™]
 primary hyperalgesia, 18, 23
 procaine, 267
 prostaglandins (PGs), 8
 ProStep, 484
 protein kinase A (PKA), 25
 protein kinase C (PKC), 25
 pseudo-addiction, 165
 pulmonary effects of poorly controlled pain, 27
 purinergic (P2X) receptors, 8
 purinoceptors, 433–434

 qualitative aspects of pain
 perception, 6
 quality of life effects of poorly controlled pain, 28

 referred pain, 3
 regeneration of damaged neurons, 16
 rehabilitative/convalescent pain, 5
 Relistor[™], 418
 remifentanyl, 150
 chemical formula, 147
 chemical name, 147
 chemical structure, 147
 common doses, 149
 contraindications, 149
 description, 148
 drug class, 147
 drug related adverse events, 150
 generic name, 147
 manufacturers, 147
 mode of activity, 148
 potential advantages, 149
 potential disadvantages, 149
 trade name, 147
 Remoxy[™], 465
 Reprexain[™], 105
 ResTiva[™], 481

 Rexista, 465
 Reye's syndrome, 253, 255
 Robafen AC[®], 98
 Robaxin[®], 368
 Robaxin, 360
 Robitussin A-C[®] Syrup, 98
 Robitussin[™] DM, 321
 rofecoxib, 213
 ropivacaine, 279
 absorption, 277
 brand names, 276
 chemical name, 276
 chemical structure,
 clinical recommendations, 279
 contraindications, 279
 description, 276
 distribution, 277
 dosing and timing, 279
 elimination, 277
 generic name, 276
 indications, 278
 mechanism of action, 277
 metabolism, 277
 pharmacokinetics, 277
 strength descriptions, 276
 toxicity, 279
 warnings, 279
 Roxicet[™], 101
 Roxicodone[®], 101
 Roxiprin[®], 101
 Rucaina, 279
 Rylomine[™], 437

 S (+) ketamine, 312
 Sabril, 292
 salicylates. *See* topical salicylates
 Sativex. *See* cannabinoid agonists
 Savella[™], 357
 scopolamine. *See* transdermal
 scopolamine
 secondary hyperalgesia, 5, 21, 23
 selective serotonin reuptake inhibitors
 (SSRIs), 338
 Sensorcaine, 274
 serotonin, 8
 serotonin and norepinephrine
 reuptake inhibitors (SNRIs), 341
 sites of analgesic activity, 62
 serotonin syndrome, 341
 silent nociceptors, 15
 Sinequan[™], 347
 Sirdalud[™], 375
 sites of analgesic activity, 62
 Skelaxin[™], 361, 372
 sodium (Na⁺) channels, 434
 Solaraze[™], 229
 Soma, 360
 somatic pain, 3, 14
 Sophidone[™], 115
 spinal cord stimulation, 35

Index

- spinothalamic tract (STT), 11
- splinting, 5
- Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP), 344
- stress response to injury, 27
- subcutaneous extended release
 - sufentanil, 467, 470
- Sublimaze™, 184
- sublingual buprenorphine, 159
- substance P, 8, 14–15
- Sufenta, 191
- sufentanil. *See* epidural sufentanil
- surgical factors
 - risk of persistent post-operative pain, 48
- Sylestin, 279
- Symmetrel®, 325
- Synera™, 286
 - contraindications, 286
 - description, 286
 - generic name, 283
 - how to use, 286
 - manufacturer, 283
 - mode of action, 286
 - pharmacology, 286
 - potential advantages, 286
 - potential disadvantages, 286
 - trade/proprietary name, 283
- Tagamet®, 391
- tamper resistant opioids,
 - Acurox™ formulation, 466
 - approaches to tamper resistance, 466
 - DETERx technology, 465
 - drug class, 463
 - EDACS, 465
 - EMBEDA™, 466
 - generic names, 463
 - manufacturers, 463
 - OROS™ technology, 465
 - prescription opioid abuse, 463
 - Remoxy™, 465
 - trade/proprietary names, 463
- Tanezumab™, 513
- tapentadol, 143–147
 - chemical formula, 143
 - chemical name, 143
 - chemical structure, 143
 - common doses, 146
 - contraindications, 146
 - description, 144
 - drug class, 143
 - drug related adverse events, 151
 - generic name, 143
 - indications, 146
 - manufacturer, 143
 - mode of activity, 146
 - potential advantages, 146
 - potential disadvantages, 147
 - relative contraindications, 146
 - trade name, 143
- tapentadol ER, 458–462
 - chemical formula, 458
 - chemical name, 458
 - chemical structure, 458
 - clinical investigations, 461
 - common doses, 461
 - contraindications, 461
 - description, 458
 - drug class, 458
 - drug related adverse events, 461
 - generic name, 458
 - indications, 459
 - manufacturer, 458
 - mode of activity, 459
 - potential advantages, 461
 - potential disadvantages, 461
 - trade name, 458
 - warnings, 461
- Tauxib, 247
- Tegretol, 292, 301
- Temesta, 365
- temporal classifications of pain, 14
 - acute pain, 13
 - chronic pain, 14
- temporal summation, 24
- Ternelin™, 375
- tetracaine. *See* Ametop Gel™; Synera™
- thermal hyperalgesia, 14
- thoracic surgery
 - risk of persistent post-operative pain, 45
- three step approach to pain management, 66
- tissue pain (nociceptive pain), 15
- tizanidine, 363, 378
 - absorption, 376
 - chemical formula, 375
 - chemical name, 375
 - chemical structure, 375
 - clinical effects, 376
 - comparative standing, 378
 - contraindications, 378
 - cost, 378
 - description, 375
 - dosing guidelines, 378
 - drug class, 375
 - drug clearance and elimination, 376
 - drug interactions, 378
 - generic name, 375
 - how supplied, 378
 - indications, 377
 - manufacturers, 375
 - metabolism, 376
 - mode of action, 376
 - pharmacokinetics, 376
 - side effects, 377
 - tablet vs. capsule, 376
 - toxicology, 378
- trade/proprietary names, 375
- Tizanidinu™, 375
- TNFα, 15
- Tofranil™, 347
- Topamax, 292
- topical capsaicin, 408
 - chemical structure, 407
 - contraindications, 409
 - description, 407
 - how to use in pain management, 409
 - mode of activity, 408
 - pharmacology, 408
 - potential advantages, 409
 - potential disadvantages, 409
 - side effects, 409
- topical local anesthetics, 285–287
 - Ametop Gel™ (amethocaine gel), 287
 - EMLA™ (Eutectic Mixture of Local Anesthetics), 285
 - generic names, 283
 - LMX-4™ (liposomal lidocaine), 285
 - manufacturers, 283
 - Synera™ (lidocaine/tetracaine topical patch), 286
 - trade/proprietary names, 283
 - vapocoolant spray (PainEase), 287
- topical salicylates, 412
 - chemical structure, 410
 - common doses/uses, 412
 - contraindications, 411
 - diethylamine salicylate, 410
 - drug related adverse events, 412
 - indications (approved/non-approved), 411
 - methyl salicylate, 410
 - mode of activity, 411
 - potential advantages, 412
 - potential disadvantages, 412
 - trolamine salicylate, 410
- Toradol™, 235
- tramadol, 137
 - advantages, 139
 - adverse events, 139
 - chemical formula, 137
 - chemical name, 137
 - contraindications, 139
 - description, 137
 - disadvantages, 139
 - drug class, 137
 - generic name, 137
 - indications, 139
 - manufacturers, 137
 - metabolism, 138
 - mode of action, 137
 - preparations, 139–140
 - structural formula, 137
 - trade/proprietary names, 137

Index

- tramadol extended release, 140–143
 - chemical formula, 140
 - chemical name, 140
 - chemical structure, 140
 - common doses, 141
 - contraindications, 141
 - description, 141
 - drug class, 140
 - drug related adverse events, 143
 - generic name, 140
 - indications, 141
 - manufacturers, 140
 - mode of activity, 141
 - potential advantages, 142
 - potential disadvantages, 143
 - trade/proprietary name, 140
- tramadol plus acetaminophen
 - adverse events, 139
 - description, 137
 - drug class, 137
 - generic name, 137
 - indications, 139
 - manufacturers, 137
 - structural formula, 137
 - trade/proprietary names, 137
- Tramal, 137
- transcutaneous electrical stimulation (TENS), 35
- Transderm Scop™, 405
- transdermal extended release
 - sufentanil, 467, 471
- transdermal scopolamine,
 - absorption, 405
 - adverse events, 407
 - chemical formula, 405
 - chemical name, 405
 - chemical structure, 405
 - common doses, 406
 - contraindications, 406
 - description, 405
 - drug class, 405
 - drug interactions, 407
 - drug related adverse events, 407
 - generic name, 405
 - indications, 406
 - major site of action, 405
 - manufacturer, 405
 - metabolism, 405
 - mode of activity, 405
 - potential advantages, 406
 - potential disadvantages, 407
 - proprietary name, 405
- TRANSDUR™, 467
- transient receptor potential (TRP) channels, 8
- Transtec™, 481
- trazodone, 351–353
 - chemical formula, 351
 - chemical name, 351
 - chemical structure, 351
 - common doses, 352
 - contraindications, 352
 - description, 351
 - disease related concerns, 353
 - drug class, 351
 - drug clearance and elimination, 351
 - drug related adverse events, 352
 - generic name, 351
 - indications, 352
 - major drug interactions, 352
 - manufacturers, 351
 - metabolic pathways, 351
 - mode of activity, 351
 - overdose, 353
 - potential advantages, 352
 - potential disadvantages, 353
 - proprietary name, 351
- tricyclic antidepressants (TCAs), 338, 350
 - chemical structure, 347
 - common doses, 350
 - contraindications, 350
 - description, 347
 - drug clearance and elimination, 348
 - drug interactions, 350
 - drug related adverse events, 350
 - generic names, 347
 - indications (non-approved), 348
 - major and minor sites of action, 347
 - manufacturers, 347
 - metabolic pathways, 348
 - mode of activity, 348
 - potential advantages, 350
 - potential disadvantages, 350
 - receptor interactions, 347
 - sites of analgesic activity, 61
 - toxicity, 350
 - trade names, 347
 - treatment of adverse events, 350
- Trileptal, 292
- Trodon, 137
- trolamine salicylate, 410
- TRPV1 ion channel blockers, 506
 - activation of TRPV1 channels, 506
 - advantages, 506
 - chemical formula, 504
 - chemical name, 504
 - chemical structure, 504
 - description, 504
 - drug class, 504
 - genetic names, 504
 - ideal TRPV1 antagonist (drug profile), 506
 - location of TRPV channels, 505
 - manufacturer/developer, 504
 - mode of action, 505
 - potential disadvantages, 506
 - potential indications, 506
 - structure of TRPV channels, 505
- TRPV-1 receptor, 8
- tumor necrosis factor-alpha (TNFα), 17
- Tussionex™, 321
- Tylenol with Codeine, 98
- Tylenol®, 256
- Ultiva®, 147
- Ultra-Brief Screening Scale for Anxiety and Depression, Patient Health Questionnaire, PHQ-4, 345
- Ultracet, 137
- Ultram, 137
- Ultram ER, 140
- uridine diphosphate-glucuronosyltransferase 2 family polypeptide B7 (UGT), 40
- valdecoxib, 213, 245
- Valium, 362, 365
- vanilloid receptors (VRI), 8
- vapocoolant spray (PainEase), 287
 - chemical structure, 287
 - contraindications, 287
 - description, 287
 - generic name, 283
 - how to use, 287
 - manufacturer, 283
 - mode of action, 287
 - pharmacology, 287
 - potential advantages, 287
 - potential disadvantages, 287
 - trade/proprietary name, 283
- vascular effects of poorly controlled pain, 27
- venous thrombotic effects of poorly controlled pain, 28
- Vicodin CR™, 452
- Vicodin™ Controlled Release, 452
- Vicoprofen™, 105
- Vioxx, 213
- visceral pain, 3, 14
- Vistaril®, 391
- Vivacaine, 274
- Vivactil™, 347
- Voltaren® Gel, 225
- Voltaren™, 229
- Voltaren-XR™, 229
- wind-up phenomenon, 9, 212
- withdrawal syndrome, 169
- World Health Organization (WHO) analgesic ladder, 66, 253
 - pain ladder method of controlling pain, 211
- Xylestesin, 279

Index

Xylocaine, 279	chemical formula, 415	manufacturer, 415
Xylocitin, 279	chemical structure, 415	metabolism, 415
Xylotox, 279	common doses, 416	mode of activity, 415
Xyzal [®] , 391	contraindications, 415	potential advantages, 416
	description, 415	potential disadvantages,
Zanaflex, 363	drug class, 415	417
Zanaflex [™] , 375	drug interactions, 417	toxicity, 416
Zantac [®] , 391	elimination, 415	trade/proprietary name, 415
Zarontin, 292	generic name, 415	Zonegran, 292
ziconotide, 415–417	indications (approved/	Zydol, 137
adverse events, 417	non-approved), 415	Zyrtec [®] , 391